Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/11/2011

EX in 2011.
  • Pfizer, Inc., Auxilium's strategic partner for XIAFLEX in Europe, and Auxilium announced that the European Commission has granted XIAPEX (the trade name under which Pfizer will market XIAFLEX in Europe) marketing authorization for the treatment of Dupuytren's contracture in adult patients with palpable cord. Pfizer and Auxilium expect XIAPEX to be available for use in some European markets later this year.

  • Fourth Quarter 2010 and Recent Corporate Highlights:

  • In March 2011, Auxilium announced that it had reached target enrollment for the double-blind, placebo-controlled Phase III program of XIAFLEX for Peyronie's disease, a condition in which scar tissue develops on the shaft of the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.  In October 2010, the Company had announced that Auxilium had dosed the first subject in this global Phase III program and that the two randomized, double-blind, placebo-controlled Phase III studies were expected to enroll at least 600 patients at approximately 70 sites in the U.S. and Australia. There is also one open label study, which is expected to enroll at least 250 patients, at approximately 30 sites in the U.S., E.U. and New Zealand, and one pharmacokinetic study, which should enroll approximately 16 patients.

  • In February 2011, Pfizer, Inc., Auxilium's strategic partner for XIAFLEX in Europe, and Auxilium announced that the European Commission has granted XIAPEX (the trade name under which Pfizer will market XIAFLEX in Europe) marketing authorization for the treatment of Dupuytren's contracture in adult patients with palpable cord. Pfizer and Auxilium expect XIAPEX to be available for use in some European markets later this year.

  • In February 2011, the Company announced that its Board of Directors amended its Rights Agreement da
    '/>"/>

  • SOURCE BioSpecifics Technologies Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
    2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
    3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
    4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
    5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
    6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
    7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
    8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
    9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
    10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
    11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... 23, 2014 Proove Biosciences , ... industry leading research and data on the association between ... American Academy of Pain Management’ s 25th ... Arizona at the , Proove Biosciences ... and genetic predisposition to opioid misuse risk in chronic ...
    (Date:9/23/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, ... consultants to its team for further development of ... proprietary cell permeable peptide platform technology derived from ... the eye. Ms. Holly ...
    (Date:9/23/2014)... Austin, TX (PRWEB) September 23, 2014 ... newest fertility clinic in South Austin, expanding a Central ... Austin and San Antonio. The satellite office for the ... and andrology options to the South Austin, Buda, Kyle ... bring effective and affordable fertility treatment directly to individuals ...
    (Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
    Breaking Biology Technology:Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
    ... of investigational sustained follicle stimulant achieves similar efficacy to ... week period in Phase III Study , , ... SGP ) today announced results from the Phase III ... corifollitropin alfa, first in the class of sustained follicle ...
    ... a subsidiary of Eisai Corporation of North America, announced ... express and develop therapeutic monoclonal antibodies for the potential ... , , Under the terms of the agreement, ... technology and its expertise to produce and develop a ...
    ... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... device and methods for linking biological agents to labels for ... as In-Line labeling, was developed for the production of radiolabeled ... A study published today in the July 2009 issue ...
    Cached Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4
    (Date:9/23/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers funded by the National Science Foundation ... inside their bodies resist melting even when temperatures ... be an undesirable consequence of the evolution of ... of Oregon doctoral student Paul Cziko, who led ...
    (Date:9/23/2014)... multidisciplinary team at the University of Wisconsin-Madison and the ... affordable way to screen for neural toxins, helping flag ... Institutes of Health (NIH) announced today that the UW-Madison ... to continue the promising work as part of the ... receive approximately $7 million over the three-year project. ...
    (Date:9/23/2014)... (PHILADELPHIA) Researchers have encountered variants or isoforms in ... accidental byproducts. A recent study, published in the journal ... called isomiRs have abundances that depend on geographic subpopulations ... a given miRNA may not be the one typically ... that microRNA isoforms are much more common than we ...
    Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3
    ... at St. Jude Children's Research Hospital have discovered how a ... effects ranging from learning and memory capabilities to glucose production ... called CREB, is a transcription factor—a molecule that binds to ... gene to make the specific protein for which it codes. ...
    ... provides the most compelling evidence to-date that some dinosaurs ... del Campo track site in Spain's Cameros Basin, contains ... a non-avian therapod dinosaur. , A team led ... La Rioja, Spain, discovered the prints in an area ...
    ... guys that help bacterial pathogens do their job of infecting ... essence, they knock down the front door of resistance and ... University of California, San Diego (UCSD) School of Medicine have ... YpkA, one of several effectors of the bacteria Yersinia – ...
    Cached Biology News:St. Jude study shows genes play an unexpected role in their own activation 2Definitive evidence found of a swimming dinosaur 2How plague-causing bacteria disarm host defense 2
    Request Info...
    Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
    in vitro Translation, Accessory Products...
    ... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
    Biology Products: